ClinicalTrials.gg
CompletedNCT03455452WITNESSUpdated Jun 16, 2026

Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer

An observational study in Renal Cell Carcinoma, Renal Cell Cancer and Adenocarcinoma Of Kidney, sponsored by Bristol-Myers Squibb. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
623
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.

Started
2018
with 2 others
Observational
9 of 42
none open now
Registered
25th of 42
by date

Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is one of 3 that started in 2018, is one of 9 observational ones, and was the 25th registered.

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a French, nationwide, prospective, observational, multi-center study in participants diagnosed with advanced renal cell carcinoma, who start a new systemic therapy with nivolumab with or without ipilimumab for the first time and within the market authorization approval.

03

Conditions studied

  • Renal Cell Carcinoma
  • Renal Cell Cancer
  • Adenocarcinoma Of Kidney
  • Adenocarcinoma, Renal Cell
  • Kidney Cancer
  • Cancer of the Kidney
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants who are at least 18 of age at the time of the treatment decision with the diagnosis of advanced renal cell cancer (RCC) (histologically or cytologically confirmed) and whose physician has already decided to initiate a treatment with nivolumab or with nivolumab plus ipilimumab for the first time for the treatment of RCC, according to the label approved in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Adult participants with the diagnosis of advanced renal cell cancer (RCC) (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab with or without ipilimumab for the first time for the treatment of RCC, according to the label approved in France

NOTE: Nivolumab with ipilimumab is indicated for the treatment of adult participants with intermediate/poor-risk advanced RCC

Exclusion criteria

Exclusion Criteria:

  • Primary diagnosis of a cancer other than advanced RCC within the past five years, ie, a cancer other than RCC that requires systemic or other treatment
  • Previously treated with anti-PD1, anti-programmed death-ligand 1 (anti-PDL1) or anti-CTLA4 therapy
  • Currently included in an interventional clinical trial for advanced or RCC. Participants who have completed participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for overall survival (OS) can be enrolled
  • Pregnant women and participants under guardianship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
623 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1: Nivolumab

    Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC

  • Cohort 2: Nivolumab + Ipilimumab

    Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC

This study also gives Nivolumab, Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    By Cohort

    Time frame: Up to 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 3 years

  2. Progression Free Survival (PFS)

    Time frame: Up to 3 years

  3. Overall Response Rate (ORR)

    Time frame: Up to 3 years

  4. Best Overall Response Rate (BORR)

    Time frame: Up to 3 years

  5. Best Overall Response (BOR)

    Time frame: Up to 3 years

  6. Distribution of socio-demographic characteristics of participants

    Time frame: Approximately 3 years

  7. Distribution of clinical characteristics of participants

    Time frame: Approximately 3 years

  8. Distribution of management of participants with treatment-related adverse events (AEs)

    Time frame: Approximately 3 years

  9. Distribution of management of participants according to Memorial Sloan Kettering Cancer Center (MSKCC) score

    Time frame: At baseline

  10. Distribution of management of participants according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score

    Time frame: At baseline

  11. Distribution of treatment patterns in participants with advanced Renal Cell Carcinoma (RCC)

    Time frame: Approximately 3 years

  12. Distribution of incidence of AEs

    Time frame: Approximately 3 years

  13. Distribution of Severity of AEs

    Time frame: Approximately 3 years

  14. Distribution of management of AEs

    Time frame: Approximately 3 years

  15. Health-related quality of life of participants using Functional Assessment of Cancer Therapy -Kidney Symptom Index (FKSI-19) questionnaires

    The FKSI-19 will be graded by the patient on a scale from 0 to 4 (range "not at all to very much")

    Time frame: Approximately 3 years

  16. Health-related quality of life of participants using European Quality of Life-5 Dimensions (EQ-5D) questionnaires

    The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (eg, no problems, moderate problems, extreme problems)

    Time frame: Approximately 3 years

07

Study locations

1 site
  • Local Institution - 0001
    Paris, 75002, France
08

References and documents

Publications

  • Barthelemy P, Albiges L, Escudier B, Narciso B, Bigot P, Chehimi M, Emambux S, Calcagno F, Mouillet G, Eymard JC, Schlurmann F, Bailly S, Garbay D, Berdah JF, Palmaro MB, Goupil MG, Spaeth D, Nere S, Quentric C, Vano YA, Thiery-Vuillemin A. Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study. ESMO Open. 2024 Jul;9(7):103602. doi: 10.1016/j.esmoop.2024.103602. Epub 2024 Jun 18. PubMed 38897136 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2025, 94 months.

Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's 94 months is above that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2018
First posted
Mar 6, 2018
StartActual
Jan 21, 2018
Primary completionActual
Dec 18, 2025
CompletionActual
Dec 18, 2025
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03455452
Responsible party
Sponsor
First posted
Mar 6, 2018
Start date
Jan 21, 2018
Primary completion
Dec 18, 2025
Completion
Dec 18, 2025
Last update
Jun 16, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion